BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Expanding Patient Eligibility in Potentially Pivotal Berubicin Trial
Jul 20, 2022
CNS Pharmaceuticals (NASDAQ: CNSP) recently announced that its global clinical trial for a potentially pivotal brain cancer treatment will expand patient eligibility following an amendment to its protocol for the study. “CNS has been enrolling patients in its phase II clinical trial for novel drug candidate Berubicin, which has shown promise in fighting the aggressive brain cancer glioblastoma (‘GBM’),” explains a recent article. “The trial will compare Berubicin’s performance to the standard of care chemotherapy agent Lomustine, aiming to establish that Berubicin is at least as effective as Lomustine and potentially better because of Berubicin’s reported capacity to cross the blood-brain barrier to attack tumors directly. Crossing the blood-brain barrier gives Berubicin novel status because other anthracycline chemotherapy agents have thus far been unable to accomplish that feat, resulting in an average life expectancy of just over a year for GBM patients once they are diagnosed with the nearly always fatal illness. The ultimate goal of the clinical trial is to establish potential improvements in overall survivability for the patients using Berubicin.”
To view the full article, visit https://ibn.fm/WGIv7
About CNS Pharmaceuticals Inc.
CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The company’s lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Additionally, the company is advancing the development of its WP1244 drug technology portfolio, which utilizes anthracycline and distamycin-based scaffolds to create small molecule agents and is believed to be 500x more potent than daunorubicin in inhibiting tumor cell proliferation. Preclinical studies of WP1244 demonstrated high uptake in the brain with antitumor activity. CNS Pharmaceuticals is evaluating the use of WP1244 in the treatment of brain cancers, pancreatic, ovarian, and lymphomas. For more information, visit the company’s website at www.CNSPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
For more information please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]
BioMedWire is part of the InvestorBrandNetwork
More News
Weil Gotshal Partners Vote to Shut Down After Nearly a Century
The large law firm, known for its powerful bankruptcy practice, started coming apart as prominent partners moved to other firms.
Lawsuit Says Republican Strategist Alex Bruesewitz Took Money From Qatari Interests
The suit claims that any payments to Alex Bruesewitz, a Republican strategist, could have violated federal law. He has denied ever taking such funds.
Claude chatbot maker set for $1.3tn stock market debut despite 'catastrophic' AI warning
The AI company behind the Claude chatbot will offer its shares at between $70 and $78, which is lower than what was expected.
Anthropic Targets Valuation of Up to $1.4 Trillion for Blockbuster I.P.O.
The A.I. company’s pricing would make it one of the biggest ever public listings. It comes at a volatile moment in markets, with investors questioning the sustainability of the A.I. boom.
Data Show Households Still Managing to Meet Their Monthly Debts
The New York Fed detailed general steadiness in debt payments for autos, student loans and mortgages.
Kim Kardashian's Skims offers refunds for $148 advent calendar after backlash
The contents of the calendar, including hair clips and keychains, have been widely criticised on social media.
Some pupils 'struggling just to get a hot meal'
Students speak out as school dinner prices are set to increase for the second time in a year.
This Law Firm Just Bought Malpractice Insurance for its A.I. Agents
The move by Crosby, an A.I. law firm, speaks to a nascent gap in coverage as major insurers grapple with risks related to artificial intelligence.
Thousands of 'off-grid' homes eligible for £250 to help with heating bills
Households dependent on either heating oil or LPG and are eligible for reduced council tax will benefit.
Failure of California Billionaire Tax Strikes Blow to Progressive Agenda
A wealth tax on billionaires seemed like a political layup. The outcome of a California ballot initiative shows otherwise.
Sales of tinned food and bottled water jump after 'Be Ready' campaign launch
Sales of essential goods such as hand sanitiser soar after the government called on households to be prepared for emergencies.
US inflation higher than expected in October - here's what is happening with prices
Prices rose by 0.4% over the month, driven by increases in shelter, food and energy costs.
YOUR NEWS, OUR NETWORK.
Do you have Great News you want to tell the world?
Be it updates about your business or your community, you can make sure that it’s heard by submitting your story to our network reaching hundreds of news sites across 6 verticals.